The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States

Latest milestone brings the Selux Next-Generation Phenotyping (NGP) platform one step closer to impacting patient care with same-shift Antibiotic Susceptibility Testing (AST).

The Funding Will Accelerate Development of an Intramuscular Formulation of a Novel Agnostic Respiratory Stimulant to Treat Life-threatening Respiratory Depression

Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test

For development of the breakthrough MultiPath platform and culture-free, anti-microbial susceptibility tests

BARDA Industry Day 2019 Attendees Hear Silverlon's Journey with BARDA; How Antimicrobial Dressings Help Agency Prepare for National Security Threats

A contract extension representing $10.7 million over two years

InDevR gearing up to launch FluChip-8G with AI interpretation of microarray 'big data' to enhance influenza surveillance